Company PHAXIAM Therapeutics S.A. Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.955 EUR | +0.17% | +1.20% | -35.76% |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 23-06-22 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 23-06-22 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-22 |
Cindy Fevre
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-22 |
Céline Breda
CTO | Chief Tech/Sci/R&D Officer | 54 | 23-06-22 |
Karine Charton
PRN | Corporate Officer/Principal | - | 23-06-22 |
General Counsel | - | 23-06-22 | |
Human Resources Officer | - | 23-06-22 | |
Jérôme Bailly
PRN | Corporate Officer/Principal | 45 | 23-06-22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 23-06-22 | |
Hilde Windels
BRD | Director/Board Member | 59 | 23-06-22 |
Gil Beyen
BRD | Director/Board Member | 62 | 23-06-22 |
Martine George
BRD | Director/Board Member | 76 | 23-06-22 |
Director/Board Member | 66 | 23-06-22 | |
Didier Hoch
CHM | Chairman | 68 | 23-06-22 |
Leila Nicolas
BRD | Director/Board Member | - | 23-06-22 |
Robert Sebbag
BRD | Director/Board Member | 73 | 23-06-22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 6,075,105 | 5,597,574 ( 92.14 %) | 250 ( 0.004115 %) | 92.14 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
250 | 0.00% | 805 $ |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- PHXM Stock
- PHXM Stock
- Company PHAXIAM Therapeutics S.A.